Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;10(3):408-17.
doi: 10.1016/j.molonc.2016.01.010. Epub 2016 Feb 10.

Clinical and biological significance of circulating tumor cells in cancer

Affiliations
Review

Clinical and biological significance of circulating tumor cells in cancer

Takaaki Masuda et al. Mol Oncol. 2016 Mar.

Abstract

During the process of metastasis, which is the leading cause of cancer-related death, cancer cells dissociate from primary tumors, migrate to distal sites, and finally colonize, eventually leading to the formation of metastatic tumors. The migrating tumor cells in circulation, e.g., those found in peripheral blood (PB) or bone marrow (BM), are called circulating tumor cells (CTCs). CTCs in the BM are generally called disseminated tumor cells (DTCs). Many studies have reported the detection and characterization of CTCs to facilitate early diagnosis of relapse or metastasis and improve early detection and appropriate treatment decisions. Initially, epithelial markers, such as EpCAM and cytokeratins (CKs), identified using immunocytochemistry or reverse transcription polymerase chain reaction (RT-PCR) were used to identify CTCs in PB or BM. Recently, however, other markers such as human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and immuno-checkpoint genes also have been examined to facilitate detection of CTCs with metastatic potential. Moreover, the epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) have also received increasing attention as important CTC markers owing to their roles in the biological progression of metastasis. In addition to these markers, researchers have attempted to develop detection or capture techniques for CTCs. Notably, however, the establishment of metastasis requires cancer-host interactions. Markers from host cells, such as macrophages, mesenchymal stem cells, and bone marrow-derived cells, which constitute the premetastatic niche, may become novel biomarkers for predicting relapse or metastasis or monitoring the effects of treatment. Biological studies of CTCs are still emerging. However, recent technical innovations, such as next-generation sequencing, are being used more commonly and could help to clarify the mechanism of metastasis. Additionally, biological findings are gradually being accumulated, adding to our body of knowledge on CTCs. In this review, we will summarize recent approaches to detect or capture CTCs. Moreover, we will introduce recent studies of the clinical and biological importance of CTCs and host cells.

Keywords: Cancer stem cell; Circulating tumor cells; Epithelial markers; Epithelial-to-mesenchymal transition; Premetastatic niche.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Circulating biomarkers in tumor metastasis. Cancer cells dissociate from primary tumors, migrate to distal sites, and finally colonize at the premetastatic niche, where mesenchymal cells facilitate metastasis by communication between cancer cells and mesenchymal cells using intercellular messengers, such as exosomes.

Similar articles

Cited by

References

    1. Aceto, N. , Bardia, A. , Miyamoto, D.T. , Donaldson, M.C. , Wittner, B.S. , Spencer, J.A. , Yu, M. , Pely, A. , Engstrom, A. , Zhu, H. , Brannigan, B.W. , Kapur, R. , Stott, S.L. , Shioda, T. , Ramaswamy, S. , Ting, D.T. , Lin, C.P. , Toner, M. , Haber, D.A. , Maheswaran, S. , 2014. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 158, 1110–1122. - PMC - PubMed
    1. Ahmed, S. , Sami, A. , Xiang, J. , 2015. HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer. 22, 101–116. - PubMed
    1. Aktas, B. , Tewes, M. , Fehm, T. , Hauch, S. , Kimmig, R. , Kasimir-Bauer, S. , 2009. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11, R46 - PMC - PubMed
    1. Ali, H.R. , Glont, S.E. , Blows, F.M. , Provenzano, E. , Dawson, S.J. , Liu, B. , Hiller, L. , Dunn, J. , Poole, C.J. , Bowden, S. , Earl, H.M. , Pharoah, P.D. , Caldas, C. , 2015. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann. Oncol. 26, 1488–1493. - PubMed
    1. Allard, W.J. , Matera, J. , Miller, M.C. , Repollet, M. , Connelly, M.C. , Rao, C. , Tibbe, A.G. , Uhr, J.W. , Terstappen, L.W. , 2004. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897–6904. - PubMed

Substances